VivoSeq
Neurology

Photosensitive Epilepsy

13

Pipeline Programs↗

0

Active Trials↗

6

Companies Involved↗

Photosensitive Epilepsy is an emerging landscape with 13 programs across 6 companies. The most active players are Eisai, Pfizer, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

56/100

Attrition Rate

44/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eisai logo

Eisai

2 programs

Phase 2Pfizer logo

Pfizer

2 programs

Phase 2Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

1 program

Phase 2Idorsia Pharmaceuticals Ltd. logo

Idorsia Pharmaceuticals Ltd.

1 program

Phase 2UCB logo

UCB

1 program

ApprovedNovartis logo

Novartis

2 programs

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

9

clinical trials

Completed5 · 56%
Terminated4 · 44%

Clinical Trials

Trial Activity

9 trials

A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive Epilepsy
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logoJohnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00579384·12 enrolled
PF-06372865 in Subjects With Photosensitive Epilepsy
Completed·Pfizer logoPfizer·Phase 2·NCT02564029·7 enrolled
Effect of BGG492 on EEG in Patients With Photosensitive Epilepsy
Completed·Novartis logoNovartis·Phase 2·NCT00784212·13 enrolled
Efficacy of YKP3089 in Patients With Photosensitive Epilepsy
Completed·SSK Life Science, Inc.·Phase 2·NCT00616148·11 enrolled
A Study to Evaluate the Effect of ACT-709478 in Photosensitive Epilepsy Patients
Completed·Idorsia Pharmaceuticals Ltd. logoIdorsia Pharmaceuticals Ltd.·Phase 2·NCT03239691·5 enrolled
Safety, Tolerability, and Efficacy of RLS103 in a Clinical Model of Photosensitive Epilepsy
Terminated·RReceptor Life Sciences·Phase 1·NCT05678881·2 enrolled
A Study to Evaluate the Pharmacodynamic Activity of E2082 in Adult Participants With Photosensitive Epilepsy
Terminated·Eisai logoEisai·Phase 2·NCT03686033·8 enrolled
A Study to Investigate the Effect of ICA-105665 in Photosensitive Epilepsy Patients
Terminated·Pfizer logoPfizer·Phase 2·NCT00979004·13 enrolled
A Study to Evaluate the Pharmacodynamic Activity of E2730 in Adult Participants With Photosensitive Epilepsy
Terminated·Eisai logoEisai·Phase 2·NCT03603639·6 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)